Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia [Phase 2]
The document describes a Phase 2 clinical trial evaluating a four-drug regimen (blinatumomab, methotrexate, cytarabine, and ponatinib) for P…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies [Phase 1, Phase 2]
A first-in-human study evaluating HLA partially to fully matched allogeneic, cryopreserved deceased donor bone marrow transplantation for va…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
A planned study to evaluate the effects of tyrosine kinase inhibitors on glucose levels and lipid metabolism in chronic myeloid leukemia pat…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase [Phase 2]
Phase 2 clinical trial evaluating the combination of ASTX727 (oral decitabine/cedazuridine) with dasatinib for newly diagnosed Philadelphia …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia [Phase 2]
This clinical trial update notes a Phase II study of asciminib as second-line treatment for chronic phase chronic myeloid leukemia, and the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) [Phase 3]
Phase 3 trial comparing Asciminib to Nilotinib in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in c…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
This update covers a prospective non-interventional study of Asciminib for adult patients with chronic myeloid leukemia in chronic phase, as…
-
EMA approval · 2026-02-05EMA Authorised: Dasatinib Accord Healthcare (Dasatinib monohydrate) — Accord Healthcare S.L.U.
EMA authorised Accord Healthcare's dasatinib monohydrate product (Dasatinib Accord Healthcare) for precursor B-cell lymphoblastic leukemia/l…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]
Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor periph…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
An observational study update evaluating dose optimization of olverembatinib in patients with chronic myeloid leukemia in chronic or acceler…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
A completed clinical trial update analyzing treatment patterns and key endpoints for patients with chronic-phase chronic myeloid leukemia in…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
This clinical trial update describes ongoing strategies for CMV infection prophylaxis and management in patients with hematologic malignanci…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial of dasatinib in patients with early chronic phase chronic myeloid leukemia has completed and results have been posted.
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple dis…
-
EMA approval · 2026-01-12EMA Authorised: Bosulif (bosutinib (as monohydrate)) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Bosulif (bosutinib) for treatment of chronic myeloid leukemia in the European Union, with Pfizer Eu…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) [Phase 1, Phase 2]
Phase 1/2 clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TERN-701 in adults with chronic …
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor [Phase 2]
A Phase 2 trial of ABL001 (asciminib) for chronic myeloid leukemia patients on tyrosine kinase inhibitors was terminated, and results have b…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Selumetinib and Azacitidine in High Risk Chronic Blood Cancers [Phase 1]
A Phase 1 clinical trial evaluating the combination of selumetinib and azacitidine in high-risk chronic myeloid leukemia and myelofibrosis i…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment [Phase 1]
Phase 1 pharmacokinetic study evaluating how hepatic impairment affects Olverembatinib exposure, to inform dosing in patients with liver dys…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Off-the-shelf NK Cells + SCT for Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating off-the-shelf natural killer (NK) cells in combination with stem cell transplantation for myeloid malignancies has …
-
EMA approval · 2025-12-19EMA Authorised: Tasigna (nilotinib) — Novartis Europharm Limited
The European Medicines Agency authorised Tasigna (nilotinib) for chronic myeloid leukemia (BCR-ABL positive); the marketing authorisation ho…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population [Phase 2]
Phase 2 clinical trial evaluating stopping tyrosine kinase inhibitors in patients with chronic myeloid leukemia who have a stable molecular …
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia [Phase 2]
A Phase 2 trial is evaluating the addition of ruxolitinib to standard tyrosine kinase inhibitor therapy for chronic myeloid leukemia in chro…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase [Phase 2]
This document describes a Phase II clinical trial evaluating dasatinib in combination with ropeginterferon alfa-2b for newly diagnosed chron…
-
FDA approval · 2025-12-15FDA Approved: NILOTINIB — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's original application for nilotinib, a generic version of the cancer drug Tasigna, for tre…